stockrow
Saturday 7 November 2026
Export ARCT’s income statement to Excel — free account
Arcturus Therapeutics Holdings Inc.
ARCT Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024.
- Revenue
- +6.68%
- EPS
- +46.9%
- Free cash flow
- +59.9%
Quarter to September 2026, against a year earlier
10.35
0.99
+10.58%
Follow ARCT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.05 | 4.01 | 6.50 | 12.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.35) | (11.29) | (9.59) | (56.39) | |
P/B ratio |
0.78 | 1.15 | 1.11 | 2.31 | |
Price to Tangible BV |
0.78 | 1.15 | 1.11 | 2.31 | |
EV/Sales |
0.15 | 1.53 | 2.56 | 9.18 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.17) | (1.43) | (1.03) | (4.48) | |
EV/FCF |
(0.17) | (1.43) | (1.03) | (4.49) | |
Quick Ratio |
6.50 | 6.19 | 5.76 | 6.56 | |
Current Ratio |
6.64 | 6.31 | 5.88 | 6.68 | |
Net Debt/EBITDA |
7.54 | 7.48 | 7.69 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.27 | 0.19 | 0.11 | 0.12 | |
Operating CF/Net income |
0.56 | 0.72 | 0.84 | 0.93 | |
Capex/Depreciation |
0.13 | 0.05 | 0.03 | 0.00 | |
Interest Coverage |
20.56 | 14.97 | 14.04 | — | |
Research and Development Expense of Revenue |
340.07% | 1,044.49% | 591.92% | 92.90% | |
Selling, General and Administrative Expense of Revenue |
194.91% | 459.24% | 371.38% | 57.30% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
94.72% | 209.85% | 142.99% | 22.09% | |
Graham Net Nets |
1.10 | 0.74 | 0.76 | 0.37 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(38.83%) | (36.40%) | (49.26%) | (22.50%) | |
Free Cash Flow Yield |
(44.38%) | (26.72%) | (38.10%) | (16.03%) | |
Revenue per Share |
0.26 | 0.07 | 0.10 | 0.64 | |
Operating CF per Share |
(0.59) | (0.68) | (0.70) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.59) | (0.68) | (0.70) | (0.24) | |
Cash per Share |
8.43 | 7.44 | 6.74 | 6.50 | |
Shareholders Equity per Share |
7.81 | 6.73 | 6.04 | 5.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.81 | 6.73 | 6.04 | 5.93 | |
Free Cash Flow |
(16.14) | (19.41) | (19.89) | (6.96) | |
Working Capital |
205.07 | 182.51 | 163.63 | 161.05 | |
Capital Expenditures |
0.09 | 0.03 | 0.02 | (0.05) | |
Net Current Asset Value |
184.28 | 162.83 | 144.66 | 142.81 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.01) | (0.02) | (0.01) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.77 | 7.96 | 9.51 | 4.60 | |
Average Payables |
5.71 | 5.14 | 7.52 | 5.63 | |
Average Assets |
307.61 | 288.60 | 266.79 | 248.83 | |
Average Common Equity |
227.48 | 212.56 | 201.43 | 196.64 |
Columns are period end dates · fundamentals updated 5 Nov 2026